UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 1-U
CURRENT REPORT PURSUANT REGULATION A
Date of Report (Date of earliest event reported) January 12, 2018
True Leaf Medicine International Ltd. | |||||||
(Exact name of registrant as specified in its charter) | |||||||
British Columbia | 000-00000 | ||||||
State or other jurisdiction of incorporation or organization | (I.R.S. Employer | ||||||
100 Kalamalka Lake Road, Unit 32, Vernon, British Columbia V1T 9G1 | |||||||
(Full mailing address of principal executive offices) | |||||||
778-389-9933 | |||||||
Issuer's telephone number, including area code | |||||||
Title of each class of securities issued pursuant to Regulation A: | Common Shares | ||||||
Item 9. Other Events
Press Release
On January 12, 2017, True Leaf Medicine International Ltd. (the "Issuer") announced that has conducted an initial closing of Regulation A+ qualified by the Securities and Exchange Commission on November 21, 2017. The intial close consisted of gross proceeds in the amount of C$6.18 million for 8,883,590 shares.
Item 10. Exhibits
15.1 Press Release dated January 12, 2018
SIGNATURES
Pursuant to the requirements of Regulation A, the issuer has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
True Leaf Medicine International Ltd.
/s/ Darcy Bomford | ||
By: | ||
Darcy Bomford | ||
Chief Executive Officer of True Leaf |
Date: January 12, 2018